Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
AlphaQuest LLC Sells 30,501 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
03:58am, Sunday, 15'th Feb 2026
AlphaQuest LLC lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 93.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Ex
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
12:34am, Friday, 06'th Feb 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
04:05pm, Thursday, 05'th Feb 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is
Stock Market Today: Major Indexes, Bitcoin Drop as Risk-Off Sentiment Grips Markets; Dow Sheds 400 Points
03:00pm, Thursday, 05'th Feb 2026
Major stock indexes and bitcoin fell sharply Thursday amid broad risk-off sentiment, as investors weighed the latest Big Tech earnings and downbeat labor data.
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
06:15pm, Wednesday, 04'th Feb 2026
/PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million
09:01am, Tuesday, 03'rd Feb 2026
Privium Fund Management sold 75,747 shares of Arrowhead Pharmaceuticals in the fourth quarter; the estimated transaction value was $3.71 million based on quarterly average prices. Meanwhile, the posit
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
01:31pm, Thursday, 29'th Jan 2026
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the com
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
04:30pm, Tuesday, 20'th Jan 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to disc
Bayforest Capital Ltd Decreases Position in Arrowhead Pharmaceuticals, Inc. $ARWR
03:48am, Wednesday, 14'th Jan 2026
Bayforest Capital Ltd reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 90.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Ex
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:06pm, Monday, 12'th Jan 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?
08:07pm, Saturday, 10'th Jan 2026
CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
11:05pm, Wednesday, 07'th Jan 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amoun
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
07:30am, Wednesday, 07'th Jan 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (pl
Arrowhead Pharmaceuticals Shares Early RNAi Obesity Data, Highlights Visceral Fat Drops and Combo Potential
05:34am, Wednesday, 07'th Jan 2026
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual key opinion leader (KOL)
